Disruptive antibody purification process employing novel inexpensive chromatography materials

While biotherapeutics offer potential treatments for some of the most debilitating diseases, the development and manufacture of these potentially life changing treatments is risky, technically challenging and expensive. This project will develop novel polymer composite materials specifically for the efficient and cost-effective manufacturing of antibody drugs. This will lead to the replacement of expensive affinity resins with inexpensive small ligand resins reducing the manufacturing cost and increasing purification efficiency. Working in partnership with BioToolomics, UCB Celltech seeks to develop an industrial-scale downstream platform process for monoclonal antibody drugs. The project will utilise modern process development methodology, combined with lifetime studies and cost of goods analysis, to fully explore the potential savings a biotherapeutic manufacturer could make by implementing the novel resins developed in the course of this project.